Impact of defective interfering particles on virus replication and antiviral host response in cell culture-based influenza vaccine production

Applied Microbiology and Biotechnology

Volumn 98, Issue 21, 2014, Pages 8999-9008

  Frensing, Timo ^a   Pflugmacher, Antje ^a   Bachmann, Mandy ^a   Peschel, Britta ^a   Reichl, Udo ^a,b  

^a MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Cell culture based vaccine production; Defective interfering particles; Influenza virus

Indexed keywords

CELL CULTURE; CELL DEATH; DEFECTS; POLYMERASE CHAIN REACTION; VACCINES;

ANTIVIRAL RESPONSE; APOPTOSIS INDUCTION; DELETION MUTANTS; INFLUENZA VACCINES; INFLUENZA VIRUS; MADIN-DARBY CANINE KIDNEY CELLS; VACCINE PRODUCTION; VIRUS REPLICATION;

VIRUSES;

ANTIVIRUS AGENT; INFLUENZA VACCINE; INTERFERON;

ANIMAL; APOPTOSIS; DOG; FLOW CYTOMETRY; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLUENZA VIRUS A; ISOLATION AND PURIFICATION; MDCK CELL LINE; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SATELLITE VIRUS; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; DEFECTIVE VIRUSES; DOGS; FLOW CYTOMETRY; HOST-PATHOGEN INTERACTIONS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INTERFERONS; MADIN DARBY CANINE KIDNEY CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL LOAD; VIRUS REPLICATION;

EID: 84920257496     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-014-5933-y     Document Type: Article

References (25)

1. Aggarwal K, Jing F, Maranga L, Liu J (2011) Bioprocess optimization for cell culture based influenza vaccine production. Vaccine 29(17):3320–3328. doi:10.1016/j.vaccine.2011.01.081
2. Audsley JM, Tannock GA (2008) Cell-based influenza vaccines: progress to date. Drugs 68(11):1483–1491
3. Balachandran S, Roberts PC, Kipperman T, Bhalla KN, Compans RW, Archer DR, Barber GN (2000) Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol 74(3):1513–1523
4. Baum A, Sachidanandam R, Garcia-Sastre A (2010) Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A 107(37):16303–16308. doi:10.1073/pnas.1005077107
5. Fulvini AA, Ramanunninair M, Le J, Pokorny BA, Arroyo JM, Silverman J, Devis R, Bucher D (2011) Gene constellation of influenza A virus reassortants with high growth phenotype prepared as seed candidates for vaccine production. PLoS ONE 6(6):e20823. doi:10.1371/journal.pone.0020823
6. Gaush CR, Smith TF (1968) Replication and plaque assay of influenza virus in an established line of canine kidney cells. Appl Microbiol 16(4):588–594
7. Genzel Y, Reichl U (2007) Vaccine production—state of the art and future needs in upstream processing. In: Pörtner R (ed) Methods in Biotechnology: Animal Cell Biotechnology - Methods and Protocols, vol 24, 2nd. Humana Press Inc., Totowa, NJ, pp 457–473
8. Genzel Y, Reichl U (2009) Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 8(12):1681–1692. doi:10.1586/erv.09.128
9. Gerdil C (2003) The annual production cycle for influenza vaccine. Vaccine 21(16):1776–1779
10. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR (2001) Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 146(12):2275–2289
11. Huang AS, Baltimore D (1970) Defective viral particles and viral disease processes. Nature 226(5243):325–327
12. Isken B, Genzel Y, Reichl U (2012) Productivity, apoptosis, and infection dynamics of influenza A/PR/8 strains and A/PR/8-based reassortants. Vaccine 30(35):5253–5261. doi:10.1016/j.vaccine.2012.05.065
13. Jennings PA, Finch JT, Winter G, Robertson JS (1983) Does the higher order structure of the influenza virus ribonucleoprotein guide sequence rearrangements in influenza viral RNA? Cell 34(2):619–627
14. Jorba N, Coloma R, Ortin J (2009) Genetic trans-complementation establishes a new model for influenza virus RNA transcription and replication. PLoS Pathog 5(5):e1000462. doi:10.1371/journal.ppat.1000462
15. Kalbfuss B, Knochlein A, Krober T, Reichl U (2008) Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 36(3):145–161
16. Kawakami E, Watanabe T, Fujii K, Goto H, Watanabe S, Noda T, Kawaoka Y (2011) Strand-specific real-time RT-PCR for distinguishing influenza vRNA, cRNA, and mRNA. J Virol Methods 173(1):1–6
17. Marcus PI, Ngunjiri JM, Sekellick MJ (2009) Dynamics of biologically active subpopulations of influenza virus: plaque-forming, noninfectious cell-killing, and defective interfering particles. J Virol 83(16):8122–8130
18. Merten OW, Hannoun C, Manuguerra JC, Ventre F, Petres S (1996) Production of influenza virus in cell cultures for vaccine preparation. Adv Exp Med Biol 397:141–151
19. Nayak DP, Chambers TM, Akkina RK (1985) Defective-interfering (DI) RNAs of influenza viruses: origin, structure, expression, and interference. Curr Top Microbiol Immunol 114:103–151
20. Roedig JV, Rapp E, Hoper D, Genzel Y, Reichl U (2011) Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin. PLoS ONE 6(12):e27989. doi:10.1371/journal.pone.0027989
21. Schulze-Horsel J, Schulze M, Agalaridis G, Genzel Y, Reichl U (2009) Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production-flow cytometry and mathematical modeling. Vaccine 27(20):2712–2722
22. Seitz C, Isken B, Heynisch B, Rettkowski M, Frensing T, Reichl U (2012) Trypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response. Appl Microbiol Biotechnol 93(2):601–611. doi:10.1007/s00253-011-3569-8
23. Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D (2001) Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19(25–26):3444–3450
24. Ulmer JB, Valley U, Rappuoli R (2006) Vaccine manufacturing: challenges and solutions. Nat Biotechnol 24(11):1377–1383. doi:10.1038/nbt1261
25. von Magnus P (1951) Propagation of the PR8 strain of influenza A virus in chick embryos. II. The formation of incomplete virus following inoculation of large doses of seed virus. Acta pathologica et microbiologica Scandinavica 28(3):278–293